Loading...
Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bon...
Na minha lista:
| Udgivet i: | J Bone Miner Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027577/ https://ncbi.nlm.nih.gov/pubmed/31233639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3735 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|